AB21844

FITC Anti-CD22 抗体 [IS7]

Name: FITC Anti-CD22 抗体 [IS7] (ab21844) | Abcam
Brand: Abcam Limited
SKU: AB21844
Price: 20000 JPY
Availability: InStock

FITC Anti-CD22 antibody [IS7]

Be the first to review this product! Submit a review

(1 Publication)

Mouse Monoclonal CD22 antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Cell preparation containing CD22 protein.

別名を表示する

CD22, SIGLEC2, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, Sialic acid-binding Ig-like lectin 2, T-cell surface antigen Leu-14, BL-CAM, Siglec-2

1 Images

Flow Cytometry - FITC Anti-CD22 antibody [IS7] (AB21844)

Flow Cyt

Unknown

Flow Cytometry - FITC Anti-CD22 antibody [IS7] (AB21844)

Overlay histogram showing peripheral blood lymphocytes stained with ab21844 (red line). The cells incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab21844, 0.5 μg/1x10⁶ cells) for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 FITC (2 μg/1x10⁶ cells ) for 30 min at 22°C. Acquisition of >5,000 events was performed.

Key facts

宿主種

Mouse

クローン性

Monoclonal

クローン番号

IS7

アイソタイプ

IgG1

標識

FITC

励起波長/蛍光波長

Ex: 495nm, Em: 519nm

キャリアフリー

交差種

Human

アプリケーション

Flow Cyt

applications

免疫原

Cell preparation containing CD22 protein. The exact immunogen used to generate this antibody is proprietary information.

P20273

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "4.15 µL for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/products/primary-antibodies/fitc-mouse-igg1-b11-6-isotype-control-ab91356'>ab91356</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>" }, "Primates": { "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" } } }

style

left-column

製品の詳細

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Affinity purification Protein G

バッファー組成

pH: 7.4 Preservative: 0.097% Sodium azide Constituents: BSA, PBS

出荷温度

Blue Ice

短期保存温度

+4°C

長期保存温度

+4°C

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

CD22 also known as Siglec-2 or B-lymphocyte cell adhesion molecule (BL-CAM) is a transmembrane protein with a mass of around 140 kDa. It is selectively expressed on the surface of mature B cells and some immature B cells. This protein plays an important role in the immune system particularly in the regulation of B cell function. CD22 functions by modulating signal transduction processes through its cytoplasmic domain which contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs).

Biological function summary

CD22 acts mainly as a negative regulator of B cell receptor (BCR) signaling. It is part of a complex that interacts with the BCR and other accessory molecules. CD22 helps maintain B cell tolerance by inhibiting overactive signaling and preventing autoimmune responses. By binding to sialic acid-containing glycans CD22 modulates interactions between B cells and other cells aiding in the maintenance of immune homeostasis.

Pathways

CD22 plays a critical role in the BCR signaling pathway and the regulation of phosphatidylinositol 3-kinase (PI3K) signaling. It works together with proteins like CD19 and SHP-1 that are key components of these pathways. By influencing these signaling cascades CD22 contributes to the modulation of B cell activation proliferation and apoptosis ensuring proper functioning of the immune response.

CD22 is associated with autoimmune conditions and hematological malignancies such as hairy cell leukemia (HCL). Therapeutic approaches targeting CD22 such as anti-CD22 antibodies are being explored for treating these diseases. CD22's role in these conditions is connected with proteins involved in the autoimmune pathways or cancer development offering potential therapeutic targets for intervention.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed : 34330755, PubMed : 8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed : 20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed : 8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed : 20516366).

See full target information CD22

style

left-column

文献 (1)

Recent publications for all applications. Explore the full list and refine your search

Oncology letters 27:14 PubMed38028179

2023

CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Ping Tian,Jinglan Deng,Cailing Ma,Ainipa Miershali,Gulikezi Maimaitirexiati,Qi Yan,Yating Liu,Hatimihan Maimaiti,Yuting Li,Changhui Zhou,Jingqin Ren,Lu Ding,Rong Li

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

FITC Anti-CD22 抗体 [IS7]

FITC Anti-CD22 antibody [IS7]

Flow Cytometry - FITC Anti-CD22 antibody [IS7] (AB21844)

関連する標識済み抗体及び組成の異なる製品 (4)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

標識

励起波長/蛍光波長

キャリアフリー

交差種

アプリケーション

免疫原

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製方法

バッファー組成

出荷温度

短期保存温度

長期保存温度

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (1)

代替製品

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

組合せ製品

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Abcam product promise